The development of new drug delivery (DD) systems able to release the drugs during prolonged periods has been receiving greater attention in recent years due to the ability to use these systems to treat diseases without human intervention. Mainly in ocular diseases with most of treatments consisting in applying eye drops which has a poor patient compliance. We are developing DD multilayers films able to release an ocular drug used in glaucoma treatment which can release the drug during a month and at specific periods of time. Biocompatible films composed of brimonidine encapsulated in ?-cyclodextrin alternated with monolayers of a hydrossoluble polymer (poly (?-amino ester)) and/or graphene oxide are able to release a precise amount of drug for a month. The ?lms growth and the pharmacokinetics were monitored by ultraviolet-visible spectroscopy, quartz crystal microbalance and atomic force microscopy. The obtained results showed that the ?lms are stable and drug release can be controlled by the presence of the hydrossoluble polymer and the graphene oxide. In particular, it was observed that graphene oxide delays signi?cantly the brimonidine release enabling precisely control the amount of drug delivered. This work contributed for new developments in DD films that can be used in glaucoma treatment or adapted to other DD systems with other types of drugs.